Snyder P J, Jacobs L S, Utiger R D, Daughaday W H
J Clin Invest. 1973 Sep;52(9):2324-9. doi: 10.1172/JCI107421.
The influence of serum triiodothyronine (T(3)) and thyroxine (T(4)) concentrations on the release of prolactin in man was studied by determining the prolactin response to synthetic thyrotropin-releasing hormone (TRH) in hypothyroid and hyperthyroid patients before and after correction of their serum thyroid hormone abnormalities. The maximum increment in serum prolactin above the basal level (maximum Delta prolactin) was used as the index of response to TRH. In 12 patients with primary hypothyroidism, the maximum Delta prolactin in response to TRH fell from 100.5+/-29.1 ng/ml (mean +/-SEM) before treatment to 36.1+/-6.0 ng/ml (P < 0.01) during the 4th wk of treatment with 30 mug T(3) + 120 mug T(4) daily. The mean serum T(3) level increased from 57+/-8 to 138+/-10 ng/100 ml, and the mean serum T(4) level increased from 3.0+/-0.4 to 7.2+/-0.4 mug/100 ml during this treatment. In eight normal subjects the maximum Deltaprolactin in response to TRH was not significantly different during the 4th wk of treatment with 30 mug T(3) + 120 mug T(4) daily from the response before treatment. In 10 patients with hyperthyroidism, the maximum Deltaprolactin in response to TRH increased from 14.2+/-2.9 ng/ml before treatment to 46.9+/-6.7 ng/ml (P < 0.001) during antithyroid treatment. The mean serum T(3) level fell from 313+/-47 to 90+/-8 ng/100 ml, and the mean serum T(4) level fell from 20.8+/-2.5 to 6.8+/-0.6 mug/100 ml during this treatment. These results show that changes from normal serum levels of T(3) and T(4) are associated with changes in prolactin responses to TRH; subnormal serum levels of T(3) and T(4) increase TRH-induced prolactin release, whereas substantially higher than normal serum levels of T(3) and T(4) inhibit this release.
通过测定甲状腺功能减退和甲状腺功能亢进患者在血清甲状腺激素异常得到纠正前后对合成促甲状腺激素释放激素(TRH)的催乳素反应,研究了血清三碘甲状腺原氨酸(T(3))和甲状腺素(T(4))浓度对人体催乳素释放的影响。血清催乳素高于基础水平的最大增加值(最大Δ催乳素)被用作对TRH反应的指标。在12例原发性甲状腺功能减退患者中,对TRH反应的最大Δ催乳素从治疗前的100.5±29.1 ng/ml降至每日服用30μg T(3)+120μg T(4)治疗第4周时的36.1±6.0 ng/ml(P<0.01)。在此治疗期间,平均血清T(3)水平从57±8升至138±10 ng/100 ml,平均血清T(4)水平从3.0±0.4升至7.2±0.4μg/100 ml。在8名正常受试者中,每日服用30μg T(3)+120μg T(4)治疗第4周时对TRH反应的最大Δ催乳素与治疗前的反应相比无显著差异。在10例甲状腺功能亢进患者中,抗甲状腺治疗期间对TRH反应的最大Δ催乳素从治疗前的14.2±2.9 ng/ml升至46.9±6.7 ng/ml(P<0.001)。在此治疗期间,平均血清T(3)水平从313±47降至90±8 ng/100 ml,平均血清T(4)水平从20.8±2.5降至6.8±0.6μg/100 ml。这些结果表明,血清T(3)和T(4)水平与正常水平的变化与催乳素对TRH反应的变化相关;低于正常水平的血清T(3)和T(4)会增加TRH诱导的催乳素释放,而显著高于正常水平的血清T(3)和T(4)则会抑制这种释放。